Myasthenia Gravis and Anxiety-Depression: Clinical and Mendelian Randomization Study

A 2026 study by Lijun Luo integrates clinical data from 96 patients with Mendelian randomization analysis. The clinical component includes patient scores like QMG and MG-ADL, while the genetic analysis uses European population genome-wide association studies. It investigates the relationship between myasthenia gravis severity and psychiatric comorbidities.

Use Cases

• Train models to predict anxiety risk in myasthenia gravis patients based on QMG and MG-ADL scores.
• Conduct statistical replication of the Mendelian randomization findings using the described genetic instrumental variables.
• Analyze the association between disease severity metrics and psychiatric symptom prevalence in a clinical cohort.

Strengths

• Clinical data includes 96 patient records with specific scale scores (QMG, MG-ADL).
• Mendelian randomization analysis uses the largest available European GWAS for the three phenotypes.
• Study employs multiple sensitivity analyses and pleiotropy tests to validate robustness.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the clinical dataset is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the European population GWAS sources.

Provenance

Source

Lijun Luo via figshare

Collection Method

Retrospective clinical analysis of 96 patients and bidirectional two-sample Mendelian Randomization.

Freshness

Last updated 2026-03-18 05:34:52; freshness should be verified.

Geography

Clinical data source unspecified; genetic data from European population studies.